ESPE Abstracts

Background: Childhood obesity, defined as having a BMI ³95th percentile for age and gender, can have serious consequences, hence; new treatments are needed. Liraglutide, a glucagon-like peptide-1 hormone, is the first FDA-approved therapy for adolescents’ obesity in over a decade. This study aim ed to evaluate the efficacy of liraglutide for weight loss and other metabolic parameters in children with obesity in Saudi Arabia.<s...